B3GNT2 promotes resistance through an orthogonal pathway by increasing poly-LacNAc on at least ten tumor ligands and receptors to reduce T cell activation, highlighting the importance of poly-LacNAc in immuno-oncology. This evidence concerns the gene B3GNT2 and neoplasm.